{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:35:06Z","timestamp":1786980906696,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"GRAIL, LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Understanding how stage at cancer diagnosis influences cause of death, an endpoint that is not susceptible to lead-time bias, can inform population-level outcomes of cancer screening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using data from 17 US Surveillance, Epidemiology, and End Results registries for 1,154,515 persons aged 50\u201384\u00a0years at cancer diagnosis in 2006\u20132010, we evaluated proportional causes of death by cancer type and uniformly classified stage, following or extrapolating all patients until death through 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Most cancer patients diagnosed at stages I\u2013II did not go on to die from their index cancer, whereas most patients diagnosed at stage IV did. For patients diagnosed with any cancer at stages I\u2013II, an estimated 26% of deaths were due to the index cancer, 63% due to non-cancer causes, and 12% due to a subsequent primary (non-index) cancer. In contrast, for patients diagnosed with any stage IV cancer, 85% of deaths were attributed to the index cancer, with 13% non-cancer and 2% non-index-cancer deaths. Index cancer mortality from stages I\u2013II cancer was proportionally lowest for thyroid, melanoma, uterus, prostate, and breast, and highest for pancreas, liver, esophagus, lung, and stomach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Across all cancer types, the percentage of patients who went on to die from their cancer was over three times greater when the cancer was diagnosed at stage IV than stages I\u2013II. As mortality patterns are not influenced by lead-time bias, these data suggest that earlier detection is likely to improve outcomes across cancer types, including those currently unscreened.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10552-023-01842-4","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T13:01:41Z","timestamp":1705582901000},"page":"849-864","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Avoiding lead-time bias by estimating stage-specific proportions of cancer and non-cancer deaths"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7169-157X","authenticated-orcid":false,"given":"Ellen T.","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina A.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham A.","family":"Colditz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison W.","family":"Kurian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Earl","family":"Hubbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"key":"1842_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/acprof:oso\/9780199214495.001.0001","volume-title":"Screening: evidence and practice","author":"AE Raffle","year":"2007","unstructured":"Raffle AE, Gray JAM (2007) Screening: evidence and practice. Oxford University Press, Oxford"},{"key":"1842_CR2","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.annonc.2021.05.806","volume":"32","author":"EA Klein","year":"2021","unstructured":"Klein EA, Richards D, Cohn A et al (2021) Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol 32:1167\u20131177. https:\/\/doi.org\/10.1016\/j.annonc.2021.05.806","journal-title":"Ann Oncol"},{"key":"1842_CR3","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1200\/JCO.2008.21.1425","volume":"27","author":"GT Armstrong","year":"2009","unstructured":"Armstrong GT, Liu Q, Yasui Y et al (2009) Late mortality among 5-year survivors of childhood cancer: a summary from the childhood cancer survivor study. J Clin Oncol 27:2328\u20132338. https:\/\/doi.org\/10.1200\/JCO.2008.21.1425","journal-title":"J Clin Oncol"},{"key":"1842_CR4","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1002\/cncr.32885","volume":"126","author":"SR Horn","year":"2020","unstructured":"Horn SR, Stoltzfus KC, Mackley HB et al (2020) Long-term causes of death among pediatric patients with cancer. Cancer 126:3102\u20133113. https:\/\/doi.org\/10.1002\/cncr.32885","journal-title":"Cancer"},{"key":"1842_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.647179","author":"Y Feng","year":"2021","unstructured":"Feng Y, Jin H, Guo K et al (2021) Causes of death after colorectal cancer diagnosis: a population-based study. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2021.647179","journal-title":"Front Oncol"},{"key":"1842_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.914875","author":"Y Ye","year":"2022","unstructured":"Ye Y, Zheng Y, Miao Q et al (2022) Causes of death among prostate cancer patients aged 40 years and older in the United States. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2022.914875","journal-title":"Front Oncol"},{"key":"1842_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1012247","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Dai Y, Liu H et al (2022) Causes of death and conditional survival estimates of long-term lung cancer survivors. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.1012247","journal-title":"Front Immunol"},{"key":"1842_CR8","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","volume":"40","author":"KM Sturgeon","year":"2019","unstructured":"Sturgeon KM, Deng L, Bluethmann SM et al (2019) A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J 40:3889\u20133897. https:\/\/doi.org\/10.1093\/eurheartj\/ehz766","journal-title":"Eur Heart J"},{"key":"1842_CR9","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/s41591-022-01745-y","volume":"28","author":"M Heinrich","year":"2022","unstructured":"Heinrich M, Hofmann L, Baurecht H et al (2022) Suicide risk and mortality among patients with cancer. Nat Med 28:852\u2013859. https:\/\/doi.org\/10.1038\/s41591-022-01745-y","journal-title":"Nat Med"},{"key":"1842_CR10","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/annonc\/mdw604","volume":"28","author":"NG Zaorsky","year":"2017","unstructured":"Zaorsky NG, Churilla TM, Egleston BL et al (2017) Causes of death among cancer patients. Ann Oncol 28:400\u2013407. https:\/\/doi.org\/10.1093\/annonc\/mdw604","journal-title":"Ann Oncol"},{"key":"1842_CR11","unstructured":"SEER (2023) Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Data, 17 Registries, Nov 2022 Sub (2000\u20132020) - Linked To County Attributes - Time Dependent (1990\u20132021) Income\/Rurality, 1969\u20132021 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2023, based on the November 2022 submission."},{"key":"1842_CR12","unstructured":"Greene FL, Page DL, Fleming ID, et al (2013) AJCC Cancer Staging Manual. Springer Science & Business Media"},{"key":"1842_CR13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/1471-2288-11-96","volume":"11","author":"TM Andersson","year":"2011","unstructured":"Andersson TM, Dickman PW, Eloranta S, Lambert PC (2011) Estimating and modelling cure in population-based cancer studies within the framework of flexible parametric survival models. BMC Med Res Methodol 11:96. https:\/\/doi.org\/10.1186\/1471-2288-11-96","journal-title":"BMC Med Res Methodol"},{"key":"1842_CR14","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1158\/1055-9965.EPI-19-1366","volume":"29","author":"CA Clarke","year":"2020","unstructured":"Clarke CA, Hubbell E, Kurian AW et al (2020) Projected reductions in absolute cancer-related deaths from diagnosing cancers before metastasis, 2006\u20132015. Cancer Epidemiol Biomarkers Prev 29:895\u2013902. https:\/\/doi.org\/10.1158\/1055-9965.EPI-19-1366","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1842_CR15","unstructured":"Surveillance Research Program, National Cancer Institute (2023) SEER*Stat software (seer.cancer.gov\/seerstat) version 8.4.1"},{"key":"1842_CR16","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.21105\/joss.01686","volume":"4","author":"H Wickham","year":"2019","unstructured":"Wickham H, Averick M, Bryan J et al (2019) Welcome to the Tidyverse. J Open Source Softw 4:1686","journal-title":"J Open Source Softw"},{"key":"1842_CR17","unstructured":"R Core Team (2022) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/."},{"key":"1842_CR18","unstructured":"US Preventive Services Task Force (2023) A and B Recommendations. https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation-topics\/uspstf-a-and-b-recommendations. Accessed 16 May 2023"},{"key":"1842_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17\u201348. https:\/\/doi.org\/10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"key":"1842_CR20","first-page":"1","volume":"70","author":"M Heron","year":"2021","unstructured":"Heron M (2021) Deaths: leading causes for 2019. Natl Vital Stat Rep 70:1\u2013114","journal-title":"Natl Vital Stat Rep"},{"key":"1842_CR21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3399\/bjgp18X696545","volume":"68","author":"KK Dobbin","year":"2018","unstructured":"Dobbin KK, Ebell M (2018) Should we expect all-cause mortality reductions in large screening studies? Br J Gen Pract 68:290\u2013291. https:\/\/doi.org\/10.3399\/bjgp18X696545","journal-title":"Br J Gen Pract"},{"key":"1842_CR22","doi-asserted-by":"publisher","first-page":"6127","DOI":"10.1002\/cam4.2476","volume":"8","author":"EAM Heijnsdijk","year":"2019","unstructured":"Heijnsdijk EAM, Csan\u00e1di M, Gini A et al (2019) All-cause mortality versus cancer-specific mortality as outcome in cancer screening trials: A review and modeling study. Cancer Med 8:6127\u20136138. https:\/\/doi.org\/10.1002\/cam4.2476","journal-title":"Cancer Med"},{"key":"1842_CR23","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1002\/1878-0261.13012","volume":"15","author":"M Kalager","year":"2021","unstructured":"Kalager M, Adami H, Lagergren P et al (2021) Cancer outcomes research\u2014a European challenge: measures of the cancer burden. Mol Oncol 15:3225\u20133241. https:\/\/doi.org\/10.1002\/1878-0261.13012","journal-title":"Mol Oncol"},{"key":"1842_CR24","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1001\/jama.2021.1077","volume":"325","author":"R Meza","year":"2021","unstructured":"Meza R, Jeon J, Toumazis I et al (2021) Evaluation of the benefits and harms of lung cancer screening with low-dose computed tomography: modeling study for the US Preventive Services Task Force. JAMA 325:988\u2013997. https:\/\/doi.org\/10.1001\/jama.2021.1077","journal-title":"JAMA"},{"key":"1842_CR25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0094-0143(02)00003-4","volume":"29","author":"JE Fowler","year":"2002","unstructured":"Fowler JE, Bigler SA (2002) Racial differences in prostate carcinogenesis: Histologic and clinical observations. Urol Clin North Am 29:183\u2013191. https:\/\/doi.org\/10.1016\/S0094-0143(02)00003-4","journal-title":"Urol Clin North Am"},{"key":"1842_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.05.034","author":"X-C Wu","year":"2011","unstructured":"Wu X-C, Eide MJ, King J et al (2011) Racial and ethnic variations in incidence and survival of cutaneous melanoma in the United States, 1999\u20132006. J Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2011.05.034","journal-title":"J Am Acad Dermatol"},{"key":"1842_CR27","doi-asserted-by":"publisher","first-page":"6315","DOI":"10.2147\/IJGM.S301837","volume":"14","author":"V Chiruvella","year":"2021","unstructured":"Chiruvella V, Guddati AK (2021) Analysis of race and gender disparities in mortality trends from patients diagnosed with nasopharyngeal, oropharyngeal and hypopharyngeal cancer from 2000 to 2017. Int J Gen Med 14:6315\u20136323. https:\/\/doi.org\/10.2147\/IJGM.S301837","journal-title":"Int J Gen Med"},{"key":"1842_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41416-020-01038-6","volume":"124","author":"VA Zavala","year":"2021","unstructured":"Zavala VA, Bracci PM, Carethers JM et al (2021) Cancer health disparities in racial\/ethnic minorities in the United States. Br J Cancer 124:315\u2013332. https:\/\/doi.org\/10.1038\/s41416-020-01038-6","journal-title":"Br J Cancer"},{"key":"1842_CR29","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jamaoncol.2015.2510","volume":"1","author":"SA Narod","year":"2015","unstructured":"Narod SA, Iqbal J, Giannakeas V et al (2015) Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol 1:888\u2013896. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2510","journal-title":"JAMA Oncol"},{"key":"1842_CR30","unstructured":"SEER (2016) SEER Quality Improvement. In: SEER. https:\/\/seer.cancer.gov\/qi\/index.html. Accessed 16 May 2023"},{"key":"1842_CR31","unstructured":"SEER (2023) Population Characteristics - SEER Registries. In: SEER. https:\/\/seer.cancer.gov\/registries\/characteristics.html. Accessed 16 May 2023"},{"key":"1842_CR32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/joim.13139","volume":"289","author":"S Eloranta","year":"2021","unstructured":"Eloranta S, Smedby KE, Dickman PW, Andersson TM (2021) Cancer survival statistics for patients and healthcare professionals\u2014a tutorial of real-world data analysis. J Intern Med 289:12\u201328. https:\/\/doi.org\/10.1111\/joim.13139","journal-title":"J Intern Med"}],"container-title":["Cancer Causes &amp; Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-023-01842-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10552-023-01842-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-023-01842-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T05:26:43Z","timestamp":1714022803000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10552-023-01842-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1842"],"URL":"https:\/\/doi.org\/10.1007\/s10552-023-01842-4","relation":{},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"value":"0957-5243","type":"print"},{"value":"1573-7225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,18]]},"assertion":[{"value":"19 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ETC, CAC, and EH are employees of GRAIL, LLC, hold stock in Illumina,\u00a0and report other support from GRAIL, LLC, during the conduct of the study. In addition, EH has multiple patents in the field of cancer detection pending to GRAIL, LLC. GAC reports other support from NIH outside of the submitted work. AWK reports a past grant from Myriad Genetics outside of the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was not subject to institutional review board approval or informed consent due to its secondary use of de-identified data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}